AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1637878 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin G
Number of subjects: 48
Study 1637878 — intervention group
Group type: COMPARATOR
Intervention: Cotrimoxazole
Number of subjects: 48
Study 6541714 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amphotericin B
Number of subjects: 32
Study 6541714 — intervention group
Group type: COMPARATOR
Intervention: Central venous catheter removal
Number of subjects: 32
Study 30659057 — intervention group
Group type: EXPERIMENTAL
Intervention: Buttonhole cannulation
Number of subjects: 50
Study 30659057 — intervention group
Group type: COMPARATOR
Intervention: Stepladder cannulation
Number of subjects: 50
Study 30053893 — intervention group
Group type: EXPERIMENTAL
Intervention: m-learning intervention (HiSense APP-ID)
Number of subjects: 200
Study 30053893 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 200
Study 27273951 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformal radiotherapy combined with radiofrequency hyperthermia
Number of subjects: 80
Study 27273951 — intervention group
Group type: COMPARATOR
Intervention: Conformal radiotherapy
Number of subjects: 80
Study 25358451 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tracheotomy (performed before day eight of MV)
Number of subjects: 489
Study 25358451 — intervention group
Group type: COMPARATOR
Intervention: Late tracheotomy (performed from day 14 if still indicated)
Number of subjects: 489
Study 23757474 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation (CHO) - 800 mL the evening before and 400 mL 2 hours before surgery
Number of subjects: 38
Study 23757474 — intervention group
Group type: COMPARATOR
Intervention: Fasting (FAST) - standard hospital protocol
Number of subjects: 38
Study 23757474 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation (CHO)
Number of subjects: 38
Study 23757474 — intervention group
Group type: COMPARATOR
Intervention: Fasting (FAST)
Number of subjects: 38
Study 19933596 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) at a target dose of 3.0 g/day
Number of subjects: 370
Study 19933596 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide (IVC) at a dose of 0.5‐1.0 g/m(2)/month
Number of subjects: 370
Study 19933596 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide (IVC)
Number of subjects: 370
Study 19933596 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 370
Study 19933596 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) and intravenous cyclophosphamide (IVC)
Number of subjects: 370
Study 18172030 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD for primary prevention
Number of subjects: 121
Study 18172030 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD for secondary prevention
Number of subjects: 121
Study 18172030 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD
Number of subjects: 121
Study 16367881 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 30 plus metformin
Number of subjects: 341
Study 16367881 — intervention group
Group type: COMPARATOR
Intervention: BIAsp 30 only
Number of subjects: 341
Study 16367881 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide plus metformin
Number of subjects: 341
Study 12679163 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement (400 kcal, 15 g protein, 50% of vitamin DRVs) and resistance exercise training
Number of subjects: 108
Study 12679163 — intervention group
Group type: COMPARATOR
Intervention: No supplementation or training (control group)
Number of subjects: 108
Study 11147228 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatment protocols for remission induction and postremission treatment in ALL
Number of subjects: 0
Study 9377606 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (10 to 150 mg once daily, most commonly 50 to 100 mg per day)
Number of subjects: 3800
Study 9377606 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 3800
Study 9377606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3800
Study 9377606 — intervention group
Group type: COMPARATOR
Intervention: Losartan and Placebo
Number of subjects: 3800
Study 8506804 — intervention group
Group type: EXPERIMENTAL
Intervention: ProAg catheter (Foley catheter coated with silver-protein)
Number of subjects: 0
Study 8506804 — intervention group
Group type: COMPARATOR
Intervention: Usual latex Foley catheter
Number of subjects: 0
Study 3470323 — intervention group
Group type: EXPERIMENTAL
Intervention: Viadent containing 0.03% sanguinaria extract (0.01% sanguinarine chloride)
Number of subjects: 12
Study 3470323 — intervention group
Group type: EXPERIMENTAL
Intervention: Hibitane Dental containing 0.2% chlorhexidine gluconate
Number of subjects: 12
Study 3470323 — intervention group
Group type: COMPARATOR
Intervention: Tap water
Number of subjects: 12
Study 3470323 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental rinse with a tripled concentration of sanguinarine chloride
Number of subjects: 12
Study 30032888 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual preconditioning (eyepatch application for ≥3 hours the day before surgery)
Number of subjects: 179
Study 30032888 — intervention group
Group type: COMPARATOR
Intervention: Programmed explanation the day before surgery (Control)
Number of subjects: 179
Study 27174798 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 2725
Study 27174798 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 2725
Study 24314696 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-of-plane approach (needle inserted at a 45‐60° angle 1cm caudal to the midpoint of the ultrasound probe just above the femoral nerve)
Number of subjects: 44
Study 24314696 — intervention group
Group type: COMPARATOR
Intervention: In-plane approach (needle inserted 0.2‐0.4 cm from the side of the probe lateral to the femoral nerve)
Number of subjects: 44
Study 22227229 — intervention group
Group type: EXPERIMENTAL
Intervention: mpHBV (modified process hepatitis B vaccine)
Number of subjects: 566
Study 22227229 — intervention group
Group type: COMPARATOR
Intervention: Control (RECOMBIVAX‐HB™)
Number of subjects: 566
Study 22227229 — intervention group
Group type: EXPERIMENTAL
Intervention: mpHBV
Number of subjects: 566
Study 22227229 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 566
Study 22227229 — intervention group
Group type: COMPARATOR
Intervention: mpHBV and Control
Number of subjects: 566
Study 20118146 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal application of xenon at a rate of 1.0 litre h(‐1) for 30 min
Number of subjects: 10
Study 20118146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 17353472 — intervention group
Group type: EXPERIMENTAL
Intervention: rtPA (recombinant tissue plasminogen activator)
Number of subjects: 1367
Study 15911152 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible-dose pregabalin (150, 300, 450, and 600 mg/day with weekly dose escalation)
Number of subjects: 338
Study 15911152 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose pregabalin (300 mg/day for 1 week followed by 600 mg/day for 11 weeks)
Number of subjects: 338
Study 15911152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study 12225612 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin III
Number of subjects: 0
Study 12225612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8143220 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (173.3 +/- 59.8 mg/day)
Number of subjects: 31
Study 8143220 — intervention group
Group type: COMPARATOR
Intervention: Control group (13 on amiodarone and 3 on beta-blockers)
Number of subjects: 31
Study 8143220 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 31
Study 3061308 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid gas-permeable (RGP) lenses (Boston IV)
Number of subjects: 0
Study 3061308 — intervention group
Group type: COMPARATOR
Intervention: Hydrogel lenses (Bausch & Lomb 'O' series)
Number of subjects: 0
Study 30908577 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 kHz stimulation (high-frequency [HF])
Number of subjects: 99
Study 30908577 — intervention group
Group type: COMPARATOR
Intervention: 10-1,500 Hz stimulation (low-frequency [LF])
Number of subjects: 99
Study 30908577 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HF and LF stimulation
Number of subjects: 99
Study 27862905 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl (INF) 2 μg/kg, maximum 100 μg
Number of subjects: 49
Study 27862905 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intranasal saline)
Number of subjects: 49
Study 25631503 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education once a week (Group C)
Number of subjects: 0
Study 25631503 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education once every ten days (Group B)
Number of subjects: 0
Study 25631503 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education once a month (Group A)
Number of subjects: 0
Study 23082885 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) therapy
Number of subjects: 0
Study 23082885 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion of previously frozen apheresis platelets
Number of subjects: 0
Study 23082885 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ASA therapy)
Number of subjects: 0
Study 21277160 — intervention group
Group type: EXPERIMENTAL
Intervention: Insall‐Burstein II (Zimmer, Warsaw, IN)
Number of subjects: 0
Study 21277160 — intervention group
Group type: EXPERIMENTAL
Intervention: Press Fit Condylar Modular (Johnson & Johnson, Raynham, MA)
Number of subjects: 0
Study 21277160 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 19635160 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 57
Study 19635160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 16722388 — intervention group
Group type: EXPERIMENTAL
Intervention: Yanshu injection combining with chemotherapy
Number of subjects: 85
Study 14742225 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadiazine 2,000 mg administered twice daily (BID)
Number of subjects: 8
Study 14742225 — intervention group
Group type: COMPARATOR
Intervention: Sulfadiazine 1,000 mg administered four times a day (QID)
Number of subjects: 8
Study 11372002 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 1200 mg/day
Number of subjects: 11
Study 11372002 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate 400 mg/day
Number of subjects: 11
Study 11372002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 9040124 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (6 mg s.c.)
Number of subjects: 15
Study 9040124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 8494582 — intervention group
Group type: EXPERIMENTAL
Intervention: tromantadine hydrochloride (ViruMerz Serol)
Number of subjects: 198
Study 8494582 — intervention group
Group type: COMPARATOR
Intervention: aciclovir
Number of subjects: 198
Study 3137067 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN)
Number of subjects: 95
Study 3137067 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 95
Study 30244294 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cholecystectomy (PC) during gastrectomy
Number of subjects: 130
Study 30244294 — intervention group
Group type: COMPARATOR
Intervention: Standard gastric surgery only (Control)
Number of subjects: 130
Study 30244294 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cholecystectomy (PC)
Number of subjects: 130
Study 28481338 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutinous brown rice (GBR) twice a day for 8 weeks
Number of subjects: 16
Study 28481338 — intervention group
Group type: COMPARATOR
Intervention: White rice (WR)
Number of subjects: 16
Study 25134853 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle-foot orthosis (AFO)
Number of subjects: 15
Study 25134853 — intervention group
Group type: COMPARATOR
Intervention: No ankle-foot orthosis (without AFO)
Number of subjects: 15
Study 21887811 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet intervention (unguided self-help intervention with a depression information website and automated cognitive behavioural therapy)
Number of subjects: 163
Study 21887811 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (free to access formal or informal help as usual)
Number of subjects: 163
Study 22987692 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted 6-minute cycling test (A6MCT)
Number of subjects: 129
Study 22987692 — intervention group
Group type: COMPARATOR
Intervention: 6-minute walk test (6MWT)
Number of subjects: 129
Study 22987692 — intervention group
Group type: COMPARATOR
Intervention: Motor Function Measure (MFM)
Number of subjects: 129
Study 19447767 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid therapy (prednisolone or equivalent)
Number of subjects: 689
Study 17590199 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (33-34 degrees C) for 72 hours
Number of subjects: 21
Study 17590199 — intervention group
Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 21
Study 15384026 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 8 mg daily for 4 weeks
Number of subjects: 29
Study 15384026 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg daily for 4 weeks
Number of subjects: 29
Study 15384026 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs (Candesartan and Enalapril)
Number of subjects: 29
Study 11755415 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental challenges with pathogenic Salmonella enterica serovar Typhi
Number of subjects: 0
Study 11755415 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccines
Number of subjects: 0
Study 11755415 — intervention group
Group type: COMPARATOR
Intervention: Large-scale controlled field trials
Number of subjects: 0
Study 11477909 — intervention group
Group type: EXPERIMENTAL
Intervention: Photo-acupuncture (101 cases)
Number of subjects: 202
Study 11477909 — intervention group
Group type: COMPARATOR
Intervention: Ear-pressing (101 cases)
Number of subjects: 202
Study 7799392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7799392 — intervention group
Group type: EXPERIMENTAL
Intervention: Various agents (gold injections, D-penicillamine, auranofin, antimalarials, azathioprine, sulfasalazine, methotrexate)
Number of subjects: 0
Study 3259099 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propofol as a bolus followed by continuous infusion
Number of subjects: 30
Study 3259099 — intervention group
Group type: COMPARATOR
Intervention: Bolus of thiopentone followed by maintenance with enflurane
Number of subjects: 30
Study 3259099 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 29050464 — intervention group
Group type: EXPERIMENTAL
Intervention: Epigallocatechin-3-gallate (EGCG)
Number of subjects: 40
Study 29050464 — intervention group
Group type: COMPARATOR
Intervention: Control (no anti-platelet medication)
Number of subjects: 40
Study 29050464 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (ASA)
Number of subjects: 40
Study 29050464 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (CPD)
Number of subjects: 40
Study 29050464 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor (TCG)
Number of subjects: 40
Study 28947466 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG) 1010 colony-forming units twice a day for 5 days
Number of subjects: 970
Study 28947466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 970
Study 28947466 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG)
Number of subjects: 970
Study 26004768 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 835
Study 23313101 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-absorptive exercise
Number of subjects: 12
Study 23313101 — intervention group
Group type: COMPARATOR
Intervention: Postprandial exercise
Number of subjects: 12
Study 21497140 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal‐SO
Number of subjects: 30
Study 21497140 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal‐SO
Number of subjects: 30
Study 21497140 — intervention group
Group type: COMPARATOR
Intervention: M1-extracephalic montage
Number of subjects: 30
Study 21497140 — intervention group
Group type: COMPARATOR
Intervention: SO-extracephalic montage
Number of subjects: 30
Study 18489937 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE) with or without medroxyprogesterone acetate (MPA)
Number of subjects: 978
Study 17165301 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cement thickness (group 1) with size 3 FRC posts cemented using adhesive plus resin cement
Number of subjects: 18
Study 17165301 — intervention group
Group type: COMPARATOR
Intervention: High cement thickness (group 2) with size 1 FRC posts cemented as in group 1
Number of subjects: 18
Study 14733469 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial breath analyzer (CBA) measuring volatile sulfur compounds (VSCs) before and after tongue debridement
Number of subjects: 30
Study 14733469 — intervention group
Group type: EXPERIMENTAL
Intervention: Organoleptic methods for breath odor evaluation
Number of subjects: 30
Study 14733469 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of tooth-brushing
Number of subjects: 30
Study 14733469 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of breath odor by mother and OBJ
Number of subjects: 30
Study 14733469 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of breath odor by evaluators and CBA
Number of subjects: 30
Study 14733469 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of interproximal restorations
Number of subjects: 30
Study 10799380 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower oil meal with beta-carotene (47 micromol)
Number of subjects: 11
Study 10799380 — intervention group
Group type: COMPARATOR
Intervention: Beef tallow meal with beta-carotene (47 micromol)
Number of subjects: 11
Study 8817983 — intervention group
Group type: EXPERIMENTAL
Intervention: Nikkiso Centrifugal Pump (HPM15)
Number of subjects: 14
Study 8817983 — intervention group
Group type: COMPARATOR
Intervention: Roller Pump (RP)
Number of subjects: 14
Study 1450043 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 48
Study 1450043 — intervention group
Group type: COMPARATOR
Intervention: Plicamycin
Number of subjects: 48
Study 3933675 — intervention group
Group type: COMPARATOR
Intervention: Olsalazine 1 g as a retention enema nightly for two weeks
Number of subjects: 100
Study 3933675 — intervention group
Group type: COMPARATOR
Intervention: Oral olsalazine 2 g daily for two weeks
Number of subjects: 100
Study 31199694 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Videogames (AVG)
Number of subjects: 49
Study 31199694 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE) + Active Videogames (AVG)
Number of subjects: 49
Study 31199694 — intervention group
Group type: COMPARATOR
Intervention: Aerobic Exercise (AE)
Number of subjects: 49
Study 29325427 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visitation (HV) intervention
Number of subjects: 122
Study 29325427 — intervention group
Group type: COMPARATOR
Intervention: Usual care services from child protection (Control)
Number of subjects: 122
Study 27090500 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventure program
Number of subjects: 438
Study 27090500 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 438
Study 23698186 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (150-300 mg/d) and Valsartan (160 mg/d)
Number of subjects: 52
Study 23698186 — intervention group
Group type: COMPARATOR
Intervention: Aliskiren (150-300 mg/d)
Number of subjects: 52
Study 22539602 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotating night shift work
Number of subjects: 640
Study 22539602 — intervention group
Group type: COMPARATOR
Intervention: Day shift work (Control)
Number of subjects: 640
Study 20443741 — intervention group
Group type: EXPERIMENTAL
Intervention: Lip muscle training with an oral screen
Number of subjects: 67
Study 20443741 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (no intervention mentioned)
Number of subjects: 67
Study 17509852 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide (inhaled twice a day for 4 weeks)
Number of subjects: 13
Study 17509852 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inhaled twice a day for 4 weeks)
Number of subjects: 13
Study 15257185 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 8-16 mg once daily
Number of subjects: 2098
Study 15257185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2098
Study 11427285 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 microg dose of hepatitis B vaccine
Number of subjects: 59
Study 11427285 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg dose of hepatitis B vaccine
Number of subjects: 59
Study 11427285 — intervention group
Group type: COMPARATOR
Intervention: Control group (baseline anti-HBs levels)
Number of subjects: 59
Study 9849709 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid receptors in peripheral mononuclear leukocytes (MNL) of PCOS patients
Number of subjects: 10
Study 9849709 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticoid receptors in peripheral mononuclear leukocytes (MNL) of healthy women (controls)
Number of subjects: 10
Study 8002670 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral potassium citrate therapy (600 mEq/day)
Number of subjects: 119
Study 8002670 — intervention group
Group type: COMPARATOR
Intervention: Untreated cases with lithiasis
Number of subjects: 119
Study 2507028 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary treatment (weight reduction, sodium restriction, decreased alcohol intake)
Number of subjects: 61
Study 2507028 — intervention group
Group type: COMPARATOR
Intervention: Drug treatment (atenolol as first choice)
Number of subjects: 61
Study 2507028 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary treatment
Number of subjects: 61